Evidence map›Paper›PMID 35130054›Full record

ArticleCirculation2022

Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial.

Iain M MacIntyre, Emma J Turtle, Tariq E Farrah, Catriona Graham, James W Dear, David J Webb, PATH-BP (Paracetamol in Hypertension–Blood Pressure) Investigators*

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01997112 (PAracetamol Treatment in Hypertension), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01997112 phase4completednot on this map

PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study

TypeinterventionalSponsorUniversity of EdinburghRan2014 to 2019Enrolled100ConditionsBlood PressureArmsParacetamol, Placebo oral capsule
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 75 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Top studies of 2022 relevant to primary care: From the PEER team.Canadian family physician Medecin de famille canadien · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Iain M MacIntyreDepartment of Renal Medicine, Royal Infirmary of Edinburgh, National Health Service Lothian, UK (I.M.M., T.E.F.).ORCID 0000-0003-4420-3822
Emma J TurtleDepartment of Renal Medicine, Royal Infirmary of Edinburgh, National Health Service Lothian, UK (I.M.M., T.E.F.).
Tariq E FarrahUniversity/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.
Catriona GrahamEdinburgh Clinical Research Facility (C.G.), University of Edinburgh, UK.
James W DearUniversity/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.
David J WebbUniversity/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.ORCID 0000-0003-0755-1756
PATH-BP (Paracetamol in Hypertension–Blood Pressure) Investigators*
British Heart Foundation · GBNHS Lothian · GBUniversity of Edinburgh · GB

Funding

British Heart Foundation FS/16/1/31699British Heart Foundation PG/13/26/30128British Heart Foundation RG/18/4/33541
6 · The paper itself

Abstract

backgroundAcetaminophen is widely used as first-line therapy for chronic pain because of its perceived safety and the assumption that, unlike nonsteroidal anti-inflammatory drugs, it has little or no effect on blood pressure (BP). Although observational studies suggest that acetaminophen may increase BP, clinical trials are lacking. We, therefore, studied the effects of regular acetaminophen dosing on BP in individuals with hypertension.

methodsIn this double-blind, placebo-controlled, crossover study, 110 individuals were randomized to receive 1 g acetaminophen 4× daily or matched placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate treatment. At the beginning and end of each treatment period, 24-hour ambulatory BPs were measured. The primary outcome was a comparison of the change in mean daytime systolic BP from baseline to end of treatment between the placebo and acetaminophen arms.

resultsOne-hundred three patients completed both arms of the study. Regular acetaminophen, compared with placebo, resulted in a significant increase in mean daytime systolic BP (132.8±10.5 to 136.5±10.1 mm Hg [acetaminophen] vs 133.9±10.3 to 132.5±9.9 mm Hg [placebo];

conclusionsRegular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo; this increases cardiovascular risk and calls into question the safety of regular acetaminophen use in this situation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01997112. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2013-003204-40.

Indexed as

AcetaminophenBlood PressureCross-Over StudiesDouble-Blind MethodFemaleHumansHypertensionMaleMiddle AgedAcetaminophenacetaminophenblood pressurecardiovascular diseasechronic painhypertension

Identifiers

PMID35130054
PMCPMC7612370
OpenAlexW4210386945

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.